These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33185803)

  • 1. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis.
    Liu J; Wang T; Zhang W; Cheng Y; He Q; Wang FS
    Hepatol Int; 2020 Dec; 14(6):958-972. PubMed ID: 33185803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W; Wu Q; Zhou J; Kong Y; You H
    Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis.
    Li M; Li Q; Qu J; Yang H; Lv T; Kong Y; Zhang H
    Hepatol Int; 2023 Feb; 17(1):52-62. PubMed ID: 36469299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.
    Zhou J; Wu X; Wei W; You H; Jia J; Kong Y
    Int J Environ Res Public Health; 2016 Jul; 13(5):. PubMed ID: 27455288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance.
    Qiu K; Liu B; Li SY; Li H; Chen ZW; Luo AR; Peng ML; Ren H; Hu P
    Aliment Pharmacol Ther; 2018 May; 47(10):1340-1348. PubMed ID: 29577360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
    Jia R; Wang WX; Gao YY; Luan JQ; Qiao F; Liu JY; Yuan JH; Cheng YQ; Wang FS; Fu JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):666-672. PubMed ID: 34371537
    [No Abstract]   [Full Text] [Related]  

  • 9. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.
    Jiang S; Guo S; Huang Y; Xu J; Li Y; Zeng Y; Guo Y; Ouyang L; Zhu C; Zhao W; Zhang Q; Guo Q; Xin H; Xie Q
    Antiviral Res; 2024 Jun; 226():105892. PubMed ID: 38663455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis.
    Fonseca MA; Ling JZJ; Al-Siyabi O; Co-Tanko V; Chan E; Lim SG
    J Viral Hepat; 2020 Jul; 27(7):650-662. PubMed ID: 32170983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.
    Chu JH; Huang Y; Xie DY; Deng H; Wei J; Guan YJ; Li GJ; Zeng YL; Yang JH; Chen XY; Shang J; Li JB; Gao N; Gao ZL
    J Viral Hepat; 2022 Sep; 29(9):765-776. PubMed ID: 35718996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
    Farag MS; van Campenhout MJH; Sonneveld MJ; Fung S; van Erpecum KJ; Wong DK; Verhey E; de Man R; De Knegt RJ; Brouwer JT; Baak HC; Feld JJ; Liem KS; Boonstra A; Hansen BE; Janssen HLA
    J Viral Hepat; 2024 Apr; 31(4):197-207. PubMed ID: 38243144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study.
    Xie Y; Zhu H; Guo Y; Ma Z; Qi X; Yang F; Mao R; Zhang J
    Can J Gastroenterol Hepatol; 2022; 2022():4325352. PubMed ID: 36531834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of the therapeutic efficacy and factors influencing sequential combination of nucleos(t)ide analogues with pegylated interferon alpha for 48~96 weeks in the treatment of patients with chronic hepatitis B].
    Jia R; Wang WX; Zhou ZP; Nie WM; Cheng YQ; Zhao J; Lian F; Luan JQ; Wang FS; Fu JL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Dec; 31(12):1290-1296. PubMed ID: 38253073
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.
    Lim SG; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lim K; Lee YM; Lee GH; Tan PS; Wai KL; Phyo WW; Khine HHTW; Lee C; Tay A; Chan E
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e228-e250. PubMed ID: 33895361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
    Liem KS; van Campenhout MJH; Xie Q; Brouwer WP; Chi H; Qi X; Chen L; Tabak F; Hansen BE; Janssen HLA
    Aliment Pharmacol Ther; 2019 Feb; 49(4):448-456. PubMed ID: 30689258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
    Yu SL; Guo CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.